Advertisement

Detection of Telomerase Activity in Patients with Pancreatic Cancer

  • Kazuhiro Mizumoto
  • Masao Tanaka
Part of the Methods in Molecular Medicine™ book series (MIMM, volume 103)

Abstract

Telomerase, which ensures the unlimited proliferation by adding TTAGGG repeat at the end of the chromosome, is strongly activated at a very high incidence in a variety of malignant neoplasms including pancreatic cancer. In addition to the acquisition of the immortality, telomerase plays an important role in the aggressive behavior of pancreatic cancer. Invasiveness of human pancreatic cancer cells correlates well with telomerase activity. Exposure of pancreatic cancer to anticancer drugs up-regulates telomerase activity, and the increase in telomerase activity correlates with resistance to the drug-induced apoptosis. More important, diagnositic values of telomerase activity are highly focused because of the lack of other specific genetic markers for pancreatic cancer. Samples of pancreatic juice are obtained at endoscopic retrograde pancreatography using a balloon catheter after intraveneous injection of secretin. Because the pancreatic juice has strong protease and RNase activity, addition of protease inhibitors and RNase inhibitors in the telomerase extraction buffer is necessary for the detection of telomerase activity in the pancreatic juice. A telomeric ladder was detected in 80% patients with carcinoma, whereas only 4.3% patients with adenoma and none with chronic pancreatitis showed positive telomerase activity.

Key Words

Telomerase diagnosis molecular marker pancreatic cancer pancreatic juice endoscopic retrograde pancreatography 

References

  1. 1.
    Harley, C. B., Futcher, A. B., and Greider, C. W. (1990) Telomeres shorten during ageing of human fibroblasts. Nature 345, 458–460.PubMedCrossRefGoogle Scholar
  2. 2.
    Shay, J. W., Werbin, H., and Wright, W. E. (1994) Telomere shortening may contribute to aging and cancer. A perspective. Mol. Cell Different. 2, 1–21.Google Scholar
  3. 3.
    Chadeneau, C., Hay, K., Hirte, H. W., et al. (1995) Telomerase activity associated with acquisition of malignancy in human colorectal cancer. Cancer Res. 55, 2533–2536.PubMedGoogle Scholar
  4. 4.
    Morin, G. B. (1989) The human telomere terminal transferase enzyme is a ribonucleoprotein that synthesizes TTAGGG repeats. Cell 88, 521–529.CrossRefGoogle Scholar
  5. 5.
    Mizumoto, K., Suehara, N., Muta, T., et al. (1996) Semi-quantitative analysis of telomerase in pancreatic ductal adenocarcinoma. J. Gastroenterol. 31, 894–897.PubMedCrossRefGoogle Scholar
  6. 6.
    Niiyama, H., Mizumoto, K., Sato, N., et al. (2001) Quantitative analysis of hTERT m RNA expression in colorectal cancer. Am. J. Gastroenterol. 96, 1895–1900.PubMedCrossRefGoogle Scholar
  7. 7.
    Sato, N., Maehara, N., Mizumoto, K., et al. (2000) Telomerase activity of cultured human pancreatic carcinoma cell lines correlates with their potential for migration and invasion. Cancer 91, 496–504.CrossRefGoogle Scholar
  8. 8.
    Sato, N., Mizumoto, K., Kusumoto, M., et al. (2000) Up-regulation of telomerase activity in human pancreatic cancer cells after exposure to etoposide. Br. J. Cancer 82, 1819–1826.PubMedCrossRefGoogle Scholar
  9. 9.
    Ksumoto, M., Ogawa, T., Mizumoto, K., et al. (1999) Adenovirus-mediated p53 gene transduction inhibits telomerase activity independent of its effects on cell cycle arrest and apoptosis in human pancreatic cancer cells. (1999) Clin. Cancer Res. 5, 2140–2147.Google Scholar
  10. 10.
    Kim, N. W., Piatyszek, M. A., Prowse, K. R., et al. (1994) Specific association of human telomerase activity with immortal cells and cancer. Science 266, 2011–2015.PubMedCrossRefGoogle Scholar
  11. 11.
    Suehara, N., Mizumoto, K., Muta, T., et al. (1997) Telomerase elevation in pancreatic ductal carcinoma compared to nonmalignant pathological states. Clin. Cancer Res. 3, 993–998.PubMedGoogle Scholar
  12. 12.
    Furuya, N., Kawa, S., Akamatsu, T., et al. (1997) Long-term follow-up of patients with chronic pancreatitis and k-ras gene mutation detected in pancreatic juice. Gastroenterology 113, 593–598.PubMedCrossRefGoogle Scholar
  13. 13.
    Casey, G., Yamanaka, Y., Friess, H., et al. (1993) p53 mutations are common in pancreatic cancer and are absent in chronic pancreatitis. Cancer Lett. 69, 151–160.PubMedCrossRefGoogle Scholar
  14. 14.
    Nakamura, Y., Tahara, E., Tahara, H., et al. (1999) Quantitative reevaluation of telomerase activity in cancerous and noncancerous gastrointestinal tissues. Mol. Carcinogen. 26, 312–320.CrossRefGoogle Scholar

Copyright information

© Humana Press Inc. 2005

Authors and Affiliations

  • Kazuhiro Mizumoto
    • 1
  • Masao Tanaka
    • 1
  1. 1.Department of Surgery and Oncology, Graduate School of Medical SciencesKyushu UniversityFukuokaJapan

Personalised recommendations